{"downloaded": true, "htmlmade": false, "full": {"id": "29976742", "source": "MED", "pmid": "29976742", "pmcid": "PMC6278989", "fullTextIdList": {"fullTextId": "PMC6278989"}, "doi": "10.3324/haematol.2018.194571", "title": "Novel lineage depletion preserves autologous blood stem cells for gene therapy of Fanconi anemia complementation group A.", "authorString": "Adair JE, Chandrasekaran D, Sghia-Hughes G, Haworth KG, Woolfrey AE, Burroughs LM, Choi GY, Becker PS, Kiem HP.", "authorList": {"author": [{"fullName": "Adair JE", "firstName": "Jennifer E", "lastName": "Adair", "initials": "JE", "authorId": {"@type": "ORCID", "#text": "0000-0003-4599-016X"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Fred Hutchinson Cancer Research Center hkiem@fredhutch.org jadair@fredhutch.org."}, {"affiliation": "University of Washington School of Medicine, Seattle, WA, USA."}]}}, {"fullName": "Chandrasekaran D", "firstName": "Devikha", "lastName": "Chandrasekaran", "initials": "D", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Fred Hutchinson Cancer Research Center."}}}, {"fullName": "Sghia-Hughes G", "firstName": "Gabriella", "lastName": "Sghia-Hughes", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Fred Hutchinson Cancer Research Center."}}}, {"fullName": "Haworth KG", "firstName": "Kevin G", "lastName": "Haworth", "initials": "KG", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Fred Hutchinson Cancer Research Center."}}}, {"fullName": "Woolfrey AE", "firstName": "Ann E", "lastName": "Woolfrey", "initials": "AE", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Fred Hutchinson Cancer Research Center."}, {"affiliation": "University of Washington School of Medicine, Seattle, WA, USA."}]}}, {"fullName": "Burroughs LM", "firstName": "Lauri M", "lastName": "Burroughs", "initials": "LM", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Fred Hutchinson Cancer Research Center."}, {"affiliation": "University of Washington School of Medicine, Seattle, WA, USA."}]}}, {"fullName": "Choi GY", "firstName": "Grace Y", "lastName": "Choi", "initials": "GY", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Fred Hutchinson Cancer Research Center."}}}, {"fullName": "Becker PS", "firstName": "Pamela S", "lastName": "Becker", "initials": "PS", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Fred Hutchinson Cancer Research Center."}, {"affiliation": "University of Washington School of Medicine, Seattle, WA, USA."}]}}, {"fullName": "Kiem HP", "firstName": "Hans-Peter", "lastName": "Kiem", "initials": "HP", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Fred Hutchinson Cancer Research Center hkiem@fredhutch.org jadair@fredhutch.org."}, {"affiliation": "University of Washington School of Medicine, Seattle, WA, USA."}]}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0003-4599-016X"}}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "11", "volume": "103", "journalIssueId": "2743063", "dateOfPublication": "2018 Nov", "monthOfPublication": "11", "yearOfPublication": "2018", "printPublicationDate": "2018-11-01", "journal": {"title": "Haematologica", "ISOAbbreviation": "Haematologica", "medlineAbbreviation": "Haematologica", "NLMid": "0417435", "ISSN": "0390-6078", "ESSN": "1592-8721"}}, "pubYear": "2018", "pageInfo": "1806-1814", "abstractText": "A hallmark of Fanconi anemia is accelerated decline in hematopoietic stem and progenitor cells (CD34 +) leading to bone marrow failure. Long-term treatment requires hematopoietic cell transplantation from an unaffected donor but is associated with potentially severe side-effects. Gene therapy to correct the genetic defect in the patient's own CD34<sup>+</sup> cells has been limited by low CD34<sup>+</sup> cell numbers and viability. Here we demonstrate an altered ratio of CD34<sup>Hi</sup> to CD34<sup>Lo</sup> cells in Fanconi patients relative to healthy donors, with exclusive <i>in vitro</i> repopulating ability in only CD34<sup>Hi</sup> cells, underscoring a need for novel strategies to preserve limited CD34<sup>+</sup> cells. To address this need, we developed a clinical protocol to deplete lineage<sup>+</sup>(CD3<sup>+</sup>, CD14<sup>+</sup>, CD16<sup>+</sup> and CD19<sup>+</sup>) cells from blood and marrow products. This process depletes >90% of lineage<sup>+</sup>cells while retaining \u226560% of the initial CD34<sup>+</sup>cell fraction, reduces total nucleated cells by 1-2 logs, and maintains transduction efficiency and cell viability following gene transfer. Importantly, transduced lineage<sup>-</sup> cell products engrafted equivalently to that of purified CD34<sup>+</sup> cells from the same donor when xenotransplanted at matched CD34<sup>+</sup> cell doses. This novel selection strategy has been approved by the regulatory agencies in a gene therapy study for Fanconi anemia patients (<i>NCI Clinical Trial Reporting Program Registry ID NCI-2011-00202; clinicaltrials.gov identifier: 01331018</i>).", "affiliation": "Fred Hutchinson Cancer Research Center hkiem@fredhutch.org jadair@fredhutch.org.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial", "Research Support, Non-U.S. Gov't", "research-article", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"grantId": "U54 DK106829", "agency": "NIDDK NIH HHS", "acronym": "DK", "orderIn": "0"}, {"grantId": "P01 HL122173", "agency": "NHLBI NIH HHS", "acronym": "HL", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "Y", "descriptorName": "Hematopoietic Stem Cells", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "Y", "descriptorName": "Fanconi Anemia", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "Y", "descriptorName": "Hematopoietic Stem Cell Transplantation"}, {"majorTopic_YN": "Y", "descriptorName": "Transduction, Genetic"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Child"}, {"majorTopic_YN": "N", "descriptorName": "Child, Preschool"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "Y", "descriptorName": "Fanconi Anemia Complementation Group A Protein", "meshQualifierList": {"meshQualifier": [{"abbreviation": "BI", "qualifierName": "biosynthesis", "majorTopic_YN": "N"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "Y", "descriptorName": "Genetic Therapy"}, {"majorTopic_YN": "N", "descriptorName": "Autografts"}]}, "chemicalList": {"chemical": {"name": "Fanconi Anemia Complementation Group A Protein", "registryNumber": "0"}}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.3324/haematol.2018.194571"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6278989"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6278989?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "5", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by-nc", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-10-09", "dateOfCreation": "2018-07-07", "firstIndexDate": "2018-07-07", "fullTextReceivedDate": "2020-07-14", "dateOfRevision": "2019-10-10", "electronicPublicationDate": "2018-07-05", "firstPublicationDate": "2018-07-05"}, "htmllinks": "https://europepmc.org/articles/PMC6278989", "abstract": "A hallmark of Fanconi anemia is accelerated decline in hematopoietic stem and progenitor cells (CD34 +) leading to bone marrow failure. Long-term treatment requires hematopoietic cell transplantation from an unaffected donor but is associated with potentially severe side-effects. Gene therapy to correct the genetic defect in the patient's own CD34<sup>+</sup> cells has been limited by low CD34<sup>+</sup> cell numbers and viability. Here we demonstrate an altered ratio of CD34<sup>Hi</sup> to CD34<sup>Lo</sup> cells in Fanconi patients relative to healthy donors, with exclusive <i>in vitro</i> repopulating ability in only CD34<sup>Hi</sup> cells, underscoring a need for novel strategies to preserve limited CD34<sup>+</sup> cells. To address this need, we developed a clinical protocol to deplete lineage<sup>+</sup>(CD3<sup>+</sup>, CD14<sup>+</sup>, CD16<sup>+</sup> and CD19<sup>+</sup>) cells from blood and marrow products. This process depletes >90% of lineage<sup>+</sup>cells while retaining \u226560% of the initial CD34<sup>+</sup>cell fraction, reduces total nucleated cells by 1-2 logs, and maintains transduction efficiency and cell viability following gene transfer. Importantly, transduced lineage<sup>-</sup> cell products engrafted equivalently to that of purified CD34<sup>+</sup> cells from the same donor when xenotransplanted at matched CD34<sup>+</sup> cell doses. This novel selection strategy has been approved by the regulatory agencies in a gene therapy study for Fanconi anemia patients (<i>NCI Clinical Trial Reporting Program Registry ID NCI-2011-00202; clinicaltrials.gov identifier: 01331018</i>).", "pdflinks": "https://europepmc.org/articles/PMC6278989?pdf=render", "journaltitle": "Haematologica", "authorinfo": ["Adair JE", "Chandrasekaran D", "Sghia-Hughes G", "Haworth KG", "Woolfrey AE", "Burroughs LM", "Choi GY", "Becker PS", "Kiem HP"], "title": "Novel lineage depletion preserves autologous blood stem cells for gene therapy of Fanconi anemia complementation group A."}